↓ Skip to main content

Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers

Overview of attention for article published in Experimental and Therapeutic Medicine, November 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#20 of 1,887)
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
1 news outlet
twitter
5 tweeters

Citations

dimensions_citation
63 Dimensions

Readers on

mendeley
109 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers
Published in
Experimental and Therapeutic Medicine, November 2015
DOI 10.3892/etm.2015.2895
Pubmed ID
Authors

CHRISTAKIS SERGIDES, MARINELA CHIRILĂ, LUIGI SILVESTRO, DAPHNE PITTA, ANDREAS PITTAS

Abstract

Over the past few decades, trans-resveratrol has received widespread attention as a preventive agent for numerous diseases. Several studies have demonstrated that it has significant biological and pharmacological properties. Trans-resveratrol has been reported to possess anti-oxidant, anti-inflammatory, anticarcinogenic, antidiabetic, anti-aging, cardioprotective and neuroprotective properties, which can be relevant in chronic diseases and longevity in humans. The aim of the present study was to investigate the rate and extend of absorption, and also the safety of resveratrol following a single 500 mg oral dose. This was an open label, single dose, one period, bioavailability study in 15 healthy volunteers under fasting conditions. Blood samples were collected at predefined time points up to 24 h after resveratrol administration, and plasma concentrations of resveratrol and its conjugated (glucuronated and sulphated) metabolites were determined using a validated high performance liquid chromatography/tandem mass spectrometry method. Pharmacokinetic parameters, including Cmax, AUC0-t, AUC0-inf, Tmax, T1/2 and MRT, were determined from plasma concentration-time profiles and found to be in good agreement with previously reported data. Cmax and AUC0-inf were lower for resveratrol when compared with the values for its glucuronated and sulphated metabolites. Cmax for resveratrol, glucuronated resveratrol and sulphated resveratrol were 71.2±42.4 ng/ml, 4,083.9±1,704.4 ng/ml and 1,516.0±639.0 ng/ml, respectively, while the AUC0-inf values were 179.1±79.1 ng/ml, 39,732.4±16,145.6 ng/ml and 14,441.7±7,593.2 ng/ml, respectively. No adverse reactions associated with resveratrol were reported during the study. The plasma concentrations of resveratrol (free and conjugated) were in agreement with those mentioned in the literature, and were adequate to promote the pharmacological activities of resveratrol. In conclusion, resveratrol 500 mg tablets were well-tolerated by all participants of the study.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 109 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 109 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 19 17%
Student > Bachelor 17 16%
Student > Ph. D. Student 14 13%
Researcher 12 11%
Other 7 6%
Other 17 16%
Unknown 23 21%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 18 17%
Agricultural and Biological Sciences 16 15%
Biochemistry, Genetics and Molecular Biology 15 14%
Medicine and Dentistry 11 10%
Chemistry 6 6%
Other 13 12%
Unknown 30 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2019.
All research outputs
#1,161,994
of 15,298,914 outputs
Outputs from Experimental and Therapeutic Medicine
#20
of 1,887 outputs
Outputs of similar age
#28,337
of 267,292 outputs
Outputs of similar age from Experimental and Therapeutic Medicine
#3
of 76 outputs
Altmetric has tracked 15,298,914 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,887 research outputs from this source. They receive a mean Attention Score of 1.9. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,292 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 76 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.